Sarepta Therapeutics price to sales ratio SRPT
Market value divided by revenue over the last twelve months, since 2018.
- Today, Nov 2, 2026
- 1.0×
- 9-year median
- 11.1×
- Against its 9-year history
- 13th
- percentile: 0 is its lowest day, 100 its highest
- 9-year range
- 0.5× to 45.3×
- Peer median
- 1.8×
Sarepta Therapeutics' price to sales ratio is 1.0× as of Nov 2, 2026.
That is below its 9-year median of 11.1×, lower than on 87% of days in the last 9 years.
Over that time it ranged from 0.5× in Jul 2025 to 45.3× in Jun 2018.
The median for 10 large drugmakers of a similar size is 1.8×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 1.0× | 0.7× | 1.2× |
| 2025 | 1.0× | 0.5× | 7.4× |
| 2024 | 7.1× | 6.1× | 11.6× |
| 2023 | 8.2× | 6.6× | 14.7× |
| 2022 | 13.0× | 7.5× | 13.0× |
| 2021 | 12.1× | 9.3× | 15.7× |
| 2020 | 27.2× | 17.8× | 32.3× |
| 2019 | 26.5× | 16.2× | 35.8× |
| 2018 | 26.3× | 24.0× | 45.3× |
Against its peers
Companies in Drug Manufacturers - General nearest Sarepta Therapeutics' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| SRPTSarepta Therapeutics | 1.0× |
| HRMYHarmony Biosciences | 2.3× |
| ANIPANI Pharmaceuticals | 1.7× |
| PBHPrestige Consumer Healthcare | 2.1× |
| PAHCPhibro Animal Health | 1.0× |
| PCRXPacira BioSciences | 1.9× |
| ANABAnaptysbio | n/m |
| NRIXNurix Therapeutics | 4.0× |
| OMEROmeros | n/m |
| AMPHAmphastar Pharmaceuticals | 1.6× |
| OGNOrganon | 0.6× |
| Peer median | 1.8× |
Where Sarepta Therapeutics ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Sarepta Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.